

## Acconeer - New market strategy communicated

Redeye provides an update following Acconeer's Q3 2024 results and updated go-to-market strategy. Net sales were below expectations while cost control remains solid, albeit partly driven by increased capitalised R&D y/y. Thus, EBITDA was better than anticipated. Inventory continues to come down, and the A2 will be finalised in 2025, with Redeye expecting low volumes in H2 2025 with ramp-up during 2026. Redeye reduces its estimates and fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Acconeer - New market strategy communicated](#)